Spyre Therapeutics, Inc.
SYRE
$103.63
$1.781.75%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 65.50M | 60.41M | 44.64M | 45.25M | 40.15M |
| Gross Profit | -65.50M | -60.41M | -44.64M | -45.25M | -40.15M |
| SG&A Expenses | 16.14M | 15.23M | 12.53M | 11.64M | 11.79M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 81.64M | 75.64M | 57.17M | 56.89M | 51.94M |
| Operating Income | -81.64M | -75.64M | -57.17M | -56.89M | -51.94M |
| Income Before Tax | -36.20M | -69.01M | -62.53M | -11.18M | -36.72M |
| Income Tax Expenses | -- | -- | 0.00 | -- | -- |
| Earnings from Continuing Operations | -36.20M | -69.01M | -62.53M | -11.18M | -36.72M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -36.20M | -69.01M | -62.53M | -11.18M | -36.72M |
| EBIT | -81.64M | -75.64M | -57.17M | -56.89M | -51.94M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.37 | -0.74 | -0.69 | -0.15 | -0.49 |
| Normalized Basic EPS | -0.56 | -0.79 | -0.52 | -0.12 | -0.48 |
| EPS Diluted | -0.37 | -0.74 | -0.69 | -0.15 | -0.49 |
| Normalized Diluted EPS | -0.56 | -0.79 | -0.52 | -0.12 | -0.48 |
| Average Basic Shares Outstanding | 84.73M | 78.55M | 75.09M | 60.41M | 60.33M |
| Average Diluted Shares Outstanding | 84.73M | 78.55M | 75.09M | 60.41M | 60.33M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |